Product Education
Amniotic Fluid vs. Cultured-Cell Exosomes: What's the Difference?
EVs obtained from a biological fluid such as amniotic fluid and EVs collected from cells expanded in culture start from different manufacturing models — and raise different due-diligence questions.
Two products can both be marketed using the word “exosomes” while coming from very different sources.
Some extracellular-vesicle products are obtained from naturally occurring biological fluids, including amniotic fluid. Others are produced by growing cells in culture and collecting the EVs those cells release.
That difference affects the manufacturing questions buyers should ask.
Here's what you should know.
Amniotic-Fluid-Derived EVs
Amniotic fluid naturally contains extracellular vesicles.
Researchers have isolated and characterized EVs from human amniotic fluid, so this isn't simply a marketing description—it is a documented biological source of extracellular vesicles.
According to KWEHEALTH-supplied information, HydroKarma is produced from refined human amniotic fluid obtained from pre-screened planned-cesarean donors through an authorized tissue-acquisition organization.
KWEHEALTH reports that the material is then quarantined and tested before subsequent processing, purification, characterization and vialing.
Importantly, this means HydroKarma is not produced by repeatedly growing cultured cells to generate EVs.
Cultured-Cell-Derived EVs
Another approach begins with cells maintained and expanded under laboratory culture conditions.
Mesenchymal stromal/stem cells (MSCs) are commonly studied for EV production, although other cell types can also be used.
The cells release EVs into their surrounding environment. Those EVs can then be collected and processed.
This creates a different set of manufacturing considerations.
For example:
- What cells are being used?
- Where did the original cells come from?
- How are the cells cultured?
- How many times have they been passaged?
- How is cellular aging or senescence controlled?
- How are the EVs collected?
- How are they purified and characterized?
- How is batch consistency evaluated?
These aren't necessarily problems with cultured-cell-derived EVs.
They're questions created by that particular manufacturing model.
Why Does Cell Passage Matter?
When cells are repeatedly expanded in culture, they undergo successive passages.
Research has shown that extended culture and replicative senescence can change cellular characteristics and can alter the cargo of MSC-derived small extracellular vesicles.
That's why passage history can matter when evaluating a cultured-cell-derived EV product.
It doesn't mean that every later-passage product is bad or that there's one universally acceptable maximum passage number.
It means the manufacturer should understand and control the process.
Read more in What Does Cell Passage Number Mean in Exosome Manufacturing?
Why Doesn't Passage Number Apply to HydroKarma the Same Way?
Because the manufacturing starting point is different.
According to KWEHEALTH, HydroKarma starts with human amniotic fluid, not a population of cells repeatedly expanded in culture for EV production.
So asking for HydroKarma's “cell passage number” would be applying a cultured-cell manufacturing question to a different production model.
For HydroKarma, more relevant questions include:
Where did the amniotic fluid come from? How was the starting material screened and handled? How was it processed and purified? How was the finished product characterized? What does the batch documentation show?
This is why understanding the source matters.
Is Amniotic Fluid Better Than Cultured Cells?
Not automatically.
There isn't enough information in the source alone to conclude that an amniotic-fluid-derived EV product is clinically superior to a cultured-cell-derived product—or vice versa.
Both approaches still require careful evaluation.
An impressive-sounding source doesn't replace:
- manufacturing controls
- purification
- characterization
- finished-product testing
- traceability
- batch-specific documentation
- appropriate storage and handling
Source tells you where to begin your evaluation. It doesn't tell you where to end it. How to Evaluate an Exosome Product Before You Buy walks through the rest.
What About Particle Count?
The same principle applies here.
Imagine an amniotic-fluid-derived product reports 50 billion EV while a cultured-cell-derived product advertises 100 billion exosomes.
The source alone doesn't decide the winner.
Neither does the larger number.
You still need to ask how the particles were measured and what characterization and testing support each product.
That's why comparing products solely by the number of billions printed on the label can be misleading.
See 50 Billion vs. 100 Billion Exosomes: Does a Higher Count Mean Better?
A Better Way to Compare EV Products
Instead of asking only:
“Which source is better?”
Compare the entire chain:
Biological source → Manufacturing controls → Processing/Purification → Characterization → Finished-product testing → Batch documentation → Storage/Handling
For a cultured-cell product, that evaluation should include questions about the cells and their expansion history.
For an amniotic-fluid-derived product, questions about donor sourcing, collection, screening, processing and finished-product characterization become especially relevant.
Different sources require different due-diligence questions.
The Bottom Line
Amniotic-fluid-derived and cultured-cell-derived EV products don't begin with the same manufacturing model.
Cultured-cell-derived EVs are collected from cells maintained and expanded under culture conditions, making factors such as cell source, culture conditions and passage history relevant.
HydroKarma, according to KWEHEALTH-supplied information, begins with refined human amniotic fluid rather than cultured-cell expansion.
That difference doesn't prove that one approach is clinically superior.
But it does tell you something important:
Before comparing exosome products, find out where they actually come from—and then ask the questions that make sense for that source.
Original Source / References
- Sheller-Miller S & Menon R — Isolation and characterization of human amniotic fluid-derived exosomes. Methods in Enzymology, 2020;645:181–194. DOI: 10.1016/bs.mie.2020.07.006 (PMID 33565971). Cited for the isolation and characterization of extracellular vesicles from human amniotic fluid. This publication does not concern HydroKarma.
- Welsh JA, Goberdhan DCI, O'Driscoll L et al. — Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. Journal of Extracellular Vesicles, 2024;13(2):e12404. DOI: 10.1002/jev2.12404 (PMID 38326288). Cited for EV nomenclature and the recommendation that EV preparations be characterized rather than described by source or a single number alone.
- Kim CG, Lee JK, Cho GJ, Shin OS, Gim JA — Small RNA sequencing of small extracellular vesicles secreted by umbilical cord mesenchymal stem cells following replicative senescence. Genes & Genomics, 2023;45(3):347–358. DOI: 10.1007/s13258-022-01297-y (PMID 35917089). Cited for the general point that replicative senescence can alter the cargo of MSC-derived small EVs. It concerns cultured MSCs and does not concern HydroKarma, and it does not define a maximum passage number.
- KWEHEALTH/HydroKarma — manufacturer-supplied documentation for HydroKarma sourcing and manufacturing. All HydroKarma-specific statements above (refined human amniotic fluid from pre-screened planned-cesarean donors via an authorized tissue-acquisition organization; quarantine and testing; processing, purification, characterization and vialing) are manufacturer-supplied; they are not findings of the independent publications above and do not establish safety or efficacy.
Continue Learning
How Can You Tell if an Exosome Company Is Legitimate?
Practical due-diligence questions for evaluating an exosome supplier: who actually manufactures the product, what batch documentation exists, and how storage and fulfillment work.
Where Do Exosomes Come From? Comparing Common Sources
Extracellular vesicles can be obtained from biological fluids such as amniotic fluid or collected from cells grown in culture. Why the source changes the questions a buyer should ask.
What Does Cell Passage Number Mean in Exosome Manufacturing?
Passage number describes how much cultured cells have been expanded. Why it's a legitimate manufacturing question for cultured-cell-derived EV products — and why it doesn't apply to every EV source.
50 Billion vs. 100 Billion Exosomes: Does a Higher Count Mean Better?
A bigger particle count isn't automatically a better product. What the number means depends on how it was measured and what characterization and batch testing support it.